Breakthrough Therapy Now Commercially Available in South America’s Most Populous Country MARLTON, N.J.–(BUSINESS WIRE)–Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the first patient in Brazil was treated with its innovative CCM® therapy delivered by the Optimizer® system. The patient was treated […]
Author: Ken Dropiewski
Capsule and Retia Medical Collaborate on Argos Cardiac Monitor to Streamline Device Interoperability, Protect Patient Safety
ANDOVER, Mass. and VALHALLA, N.Y., Jan. 5, 2021 /PRNewswire/ — Retia Medical is the first company to utilize Capsule Technologies’ new Device Driver Interface (DDI) development strategy to integrate its Argos Cardiac Monitor, the companies announced today. Capsule’s new DDI development strategy uses the Integrating Healthcare Enterprise-Patient Care Device (IHE-PCD) framework to speed device connectivity […]
BioSerenity Announces FDA Clearance for Electroencephalography (EEG) Wearable Device System
Neuronaute® EEG System and IceCap® bring Comprehensive Remote Electroencephalography Monitoring Services to People Living with Neurological Disorders. PARIS and ATLANTA, Jan. 5, 2021 /PRNewswire/ — BioSerenity, Inc., a leading global provider of remote diagnostic solutions in the areas of Neurology, Cardiology and Sleep Disorders announced today it received U.S. Food and Drug Administration (FDA) 510(k) […]
Emboline™ Raises Over $10 Million in Series C Funding to Fund Further Development of the Emboliner™ Embolic Protection Catheter to Minimize Stroke Risk From TAVR
In the SafePass 2 clinical study, the Emboliner™ demonstrated excellent safety and technical performance, and captured five times more debris than commercially-available devices SANTA CRUZ, Calif., Jan. 5, 2021 /PRNewswire/ — Emboline, Inc., a privately held medical technology company focused on reducing stroke during transcatheter heart procedures, today announced it completed raising over $10 […]
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
Paul Verrastro Named CMO and Thomas Hengsteler Named VP of European Sales and Marketing MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding its senior leadership team by adding two medical […]
Biotricity Submitted 510(k) U.S. FDA Filing for Biotres
Biotres is a compact and discreet 3 channel holter solution REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December 31 2020, for Biotres. The company expects this process to take […]
PhysIQ Elects Former Vice Admiral Raquel C. Bono, M.D. to Advisory Board
CHICAGO–(BUSINESS WIRE)–physIQ announced today that Raquel C. Bono, M.D., a board-certified trauma surgeon and retired Vice Admiral of the United States Navy Medical Corps, has been selected as a member of the company’s Advisory Board. Dr. Bono retired from the Navy in 2019 as Chief Executive Officer and Director for the […]
Stacy Enxing Seng Joins the Vesper Medical Board of Directors
Wayne, PA, January 4, 2021 Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, […]
Dr. Michael Siropaides Joins Modern Heart & Vascular Institute
Esteemed Board-Certified Cardiologist Michael Siropaides, MD joins Modern Heart and Vascular Institute, bringing 30 years of excellent bedside cardiovascular skills and experience. HOUSTON, Jan. 4, 2021 /PRNewswire/ — Modern Heart and Vascular Institute welcomes Michael Siropaides, MD to the team. Dr. Siropaides has been practicing cardiovascular medicine for thirty-plus years. His energy and passion […]
Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted LYPDISO™ as the […]



